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The Role of Gender in the Onset, 
Development and Impact of 
Type 2 Diabetes Mellitus and Its 
Co-Morbidities
Féaron C. Cassidy, Sinead Lafferty and Cynthia M. Coleman
Abstract
Almost half a billion people worldwide are living with diabetes mellitus (DM). 
Complications associated with DM are common and approximately half of those 
people with DM suffer from at least one comorbidity. There is high mortality, mor-
bidity and cost associated with these comorbidities which include cardiovascular 
disease, retinopathy, nephropathy, neuropathy and osteopathy. Gender influences 
the relative risk of developing complications from DM via differing mechanisms – 
both directly and indirectly. Generally, an increased relative risk of cardiovascular 
disease and kidney disease is noticed in women with DM compared to the non-DM 
context, where rates of both are much higher in men. Men appear to be at greater 
risk of diabetic retinopathy and also of insensate diabetic neuropathy, whereas 
women suffer from an increased rate of painful diabetic neuropathy compared to 
men. These differences are not clear cut and vary regionally and temporally, indi-
cating that the field would benefit from further research on both the epidemiology 
and physiological mechanism of the observed patterns. These differences should be 
taken into account in treatment programmes for DM and its comorbidities.
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1. Introduction
Diabetes mellitus (DM) is a metabolic disease characterised by elevated blood 
glucose levels resultant of insufficient production or action of insulin, resulting 
in Type 1 (T1DM) and Type 2 (T2DM) respectively. Chronic hyperglycaemia 
is responsible for an array of severe macro- and micro-vascular complications 
resulting in numerous health complications. These include cardiovascular disease, 
retinopathy, nephropathy, neuropathy and osteopathy. Globally, more than 450 mil-
lion adults are living with DM, while the annual death toll of DM is over 4 million 
people [1]. 70% of recorded deaths where T2DM is a contributing factor are due to 
T2DM comorbidities rather than T2DM itself, indicating insufficient or ineffective 
treatment of comorbidities [1, 2]. This statistic emphasises the importance of treat-
ing not only T2DM but also the complications associated with it, which are often 
present despite seemingly effective T2DM management.
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The cost of treating T2DM includes the direct management of the disease with 
medication and medical visits as well as that of treating the associated complica-
tions and comorbidities which account for 53% of the total cost of T2DM patient 
care [3]. This puts the annual global healthcare expenditure on complications alone 
at $324 billion as of 2014 [4]. The continued increase in the healthcare budget 
spending on DM complications tracks the overall increased prevalence of the 
disease, but is also dependent on the likelihood of those complications within the 
DM population. Age is positively correlated with both onset of T2DM and its com-
plications [5, 6]. In some middle income countries T2DM per capita is approaching 
30% and increasing, these extraordinarily high rates of disease are intersecting 
with increasing life expectancy, which is also increasing fastest in middle-income 
countries [7, 8]. This will further compound the prevalence of T2DM complica-
tions and the associated morbidity, mortality and financial costs as the duration of 
disease and the average age of people living with it increases [9].
Despite a slightly increased prevalence of DM in men than women, more women 
than men die from DM and its associated complications [1]. Here we discuss the 
contribution of gender as a variable in the development of T2DM, its associated 
comorbidities and resulting mortality rates.
2. Gender differences in DM prevalence and mortality
The global prevalence of DM in adults aged 20–79 years is 9.3%, with slightly 
fewer women (9%) than men (9.6%) estimated to be living with the disease [1]. 
Prevalence of DM is increasing globally and though there is some evidence in 
high-income countries that incidence level is stabilising, the incidence in low- and 
middle-income countries continues to increase [1, 10]. The overall global preva-
lence of DM continues to increase both due to this increased incidence and due to 
the reduced mortality associated with DM as diagnosis and treatment continue to 
improve.
The major risk factors for the development of T2DM are obesity and poor diet. 
The higher prevalence of DM among men is despite generally higher rates of obesity 
in women globally - 15% of women and 11% of men were estimated to be in the 
obese category in 2016 [11, 12]. This epidemiological finding has been supported by 
studies at the individual level, which demonstrate that men have increased insulin 
resistance and develop T2DM at a younger age and lower BMI than women. This 
is primarily due to their overall propensity for visceral and hepatic deposition of 
lipid [11, 13–16]. In contrast, women tend to experience preferential subcutaneous 
deposition of lipid. These female and male pattern adipose distributions, com-
monly referred to as pear- and apple-shaped obesity respectively, are regulated by 
sex hormones and apple/central adiposity is independently correlated with T2DM 
status irrespective of BMI or gender [16, 17]. Though this bias exists currently and 
on a global level, there is high geographical and temporal variability [1, 18]. Despite 
men’s physiologically higher propensity toward the development of T2DM, up until 
recently higher prevalence was recorded in women than men globally, and still is in 
many regions [1, 18]. This statistic correlates with what is known about obesity, a 
robust predictor of T2DM [19].
Although obesity has been recognised since ancient times, it effected a very 
low proportion of the population even up until the 1960s (1–2% in England at the 
time) and has only been described as posing a serious threat to public health in the 
last 50 years [20]. This rapid onset of obesity at the population level has correlated 
with the change in lifestyle and diet associated with development and westernisa-
tion, and, has disproportionately affected women [19]. In all countries assessed, 
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the prevalence of obesity is higher in women during the growth phase of increasing 
obesity prevalence within that country [19, 21–26]. Only as obesity levels stabilise 
does the prevalence of obesity in men reach that of women [27, 28]. As would be 
expected, this generally tracks with what is known regarding the prevalence of 
T2DM in women and men over time. 100 years ago, rates of T2DM were higher 
in women in all regions assessed [18, 29]. Now in 2020, Europe, North America, 
South-East Asia and the Western pacific IDF regions have recorded either higher 
rates in men or no difference between genders, while the Africa, Middle East and 
Central America regions record higher rates of T2DM in women [1].
This may in part explain why despite their metabolically preferential adipose 
expansion, and lower propensity to T2DM itself, women have higher DM-associated 
mortality, with 2.3 million women and 1.9 million men dying from DM or 
DM-associated complications in 2019 alone [1, 7, 30, 31]. However, considering the 
majority of T2DM-associated mortality is due to associated complications rather 
than T2DM itself, this also indicates a higher risk of either developing complica-
tions or to enhanced severity of those complications in women. The IDF also record 
increased spending on women with T2DM than men, which may reflect higher rates 
of comorbidity in this group [1]. Whether gender impacts comorbidity outcomes in 
response to T2DM has been assessed in studies investigating individual complica-
tions, these are discussed below.
2.1 Cardiovascular disease
Cardiovascular disease (CVD), including cardiomyopathy, congestive heart 
failure, stroke and peripheral arterial disease, is the most prevalent cause of both 
morbidity and mortality in patients with DM [32–35]. The increased risk of death 
from CVD compared to the general population has been estimated at being between 
1.6 and 2.6 times greater in individuals with T2DM depending on the form of 
CVD [1, 36–38].
The T2DM milieu increases CVD risk via a number of pathways. Atherosclerosis 
build-up is accelerated by the combination of hyperglycaemia, insulin resistance 
and increased free fatty acid release. In tandem, blood pressure is increased; 
hyperglycaemia impedes the production of nitric oxide (NO), while free fatty 
acid release resultant from insulin resistance reduces the bioavailability of NO 
(reviewed in [39]). NO has a vasoprotective role through increasing vasodilation, 
and therefore reducing blood pressure, as well as inhibiting inflammation and 
platelet activation [40]. The upregulation of inflammatory signalling pathways, 
including AGEs (advanced glycation end-products) and their receptor; RAGE, 
further promotes plaque deposition (reviewed in [39, 41]). The culmination of 
these processes is a patient at high risk of cardiovascular insult. While rates of CVD 
have decreased in patients with and without T2DM over the past few decades, risk 
of an event and risk of mortality from CVD remain higher in patients with T2DM 
[42, 43]. This is at least in part due to high rates of inability to achieve glycaemic 
control, but even in cases of robust glucose control, there is an increased level of 
risk that remains, indicating a metabolic memory of the hyperglycaemia present 
prior to control of T2DM [44]. This is exacerbated the longer the person has been 
diagnosed with T2DM. The mode of modulation of this metabolic memory is 
discussed in Cooper et al. [45], where both epigenetic mechanisms and immune 
memory are put forward. The treatment of patients with T2DM with standard 
CVD treatment regimens largely ameliorates this risk [46].
In women there is a 44% greater T2DM-associated risk of coronary heart disease 
(CHD) than in men [47]. The vastly increased risk of CVD in T2DM-diagnosed 
women is so great that it has been proposed as the primary attribute accounting for 
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high diabetes-associated mortality in this population [30], see Table 1. In the general 
population men are at greater risk for CVD which is explained by the protective 
functions of oestrogens [54]. Primarily estradiol, for which there is receptors on car-
diomyocytes, acts in a cardioprotective manner with numerous mechanisms for its 
action described in the literature (by improving mitochondrial function and reduc-
ing reactive oxygen species (ROS), via anti-fibrotic action in extracellular matrix 
remodelling, by stimulation of angiogenesis, via eNOS-dependent vasodilation, or 
possibly via aromatase action) as reviewed in Iorga et al., 2017 [55]. It is hypothesised 
that T2DM reverses the protective functions of oestrogens via immune-modulation 
[48]. As well as this increased disease burden, women with CHD and T2DM are 
at a nearly three times higher risk of death from CHD than men with CHD and 
T2DM [52]. A statistic that is likely related to the fact that women are less likely to be 
prescribed appropriate blood pressure and lipid lowering drugs [56–60].
Androgens, hormones which promote the development of male characteristics 
in vertebrates, have been shown to up-regulate the expression of known athero-
sclerosis associated genes in monocyte-derived macrophages from male donors but 
not from female donors [47]. However, men with hypogonadotropic hypogonadism 
(decreased androgen levels) have worse cardiovascular health and outcomes and 
are at increased risk of T2DM [61, 62]. Additionally, testosterone therapy has been 
shown to increase lean mass and insulin sensitivity in a small study of men with this 
condition [63].
As is the case with CHD, T2DM has been identified as an independent risk factor 
for stroke with a relative risk of 2.1 compared to the general population [64]. In the 
non-diabetic population, women have a higher lifetime risk of stroke despite lower 
risk in the majority of age categories [65]. Their risk increases over the age of 85 and 
the higher life time risk is a likely a factor of this combined with women’s longer 
life expectancy [65]. Additionally, that female gender is associated with poorer 
outcome and increased risk of post-stroke disability is due to both differences in the 
types of strokes experienced by women and men and the significantly older age at 
which women experience stroke [65]. Women diagnosed with T2DM are at a 27% 
greater risk of stroke compared to men with T2DM, an effect which correlates with 
HbA1c levels [66]. Women are also less likely to achieve target levels for HbA1c [67]. 
Additionally, each 1% increase from baseline HbA1c is associated with a 5% increase 
in risk of stroke for women whereas the same increase from baseline in men is only 
associated with a 1% increase in risk of stroke [66]. This association is stronger in 
women over 55 years of age than those under 55, supporting a protective role of 
oestrogens, which are lost following menopause [68].
Study 
location




14.40 2.90 Juutilainen et al. 2004 [48]
USA CHD mortality 3.30 1.90 Barrett-Connor et al. 1991 [49]
Italy Stroke 2.56 1.89 Policardo et al. 2015 (varied by age) [50]
Asia 
Pacific
CHD mortality 2.54 2.03 Woodward et al. 2003 [51]
Taiwan CHD mortality 2.46 1.83 Lin et al. 2013 [52]
USA PAD 1.72 2.12 Palumbo & Joseph Melton III 1995 [53]
Table 1. 
T2DM hazard ratio for CVD events by gender.
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While a number of studies have found women with DM at higher risk of stroke, 
Dhamoon et al. found that this increased risk disappeared when other factors 
including medication were accounted for [69]. This highlights a trend in the treat-
ment of women in general for CVD, whereby a focus by doctors and the public on 
men’s cardiovascular health has resulted in a greater risk to women who have not 
received a similar increase in attention to symptoms and biomarkers [70].
2.2 Diabetic retinopathy
Diabetic retinopathy is a leading cause of preventable visual impairment, 
effecting many in the working age demographic with significant personal and 
socioeconomic consequences [1]. It presents in approximately one third of patients 
with DM [71]. There are two main forms of diabetic retinopathy: nonproliferative 
and proliferative diabetic retinopathy. Nonproliferative retinopathy, also known as 
background diabetic retinopathy, is the early stages of the disorder in which hyper-
glycaemia leads to vascular cell apoptosis and neural damage within the retina but 
without major symptoms or an effect on vision. Proliferative diabetic retinopathy 
is the advanced form of diabetic retinopathy which is brought on by progressive 
retinal ischemia and results in vision loss through complications such as retinal 
detachment, neovascular glaucoma and vitreous haemorrhage [72].
Men appear to be at greater risk than women of developing diabetic retinopathy 
as well as progressing to proliferative retinopathy [73], see Table 2. Interestingly this 
pattern was not found in a large study in China [78], where there was found to be no 
effect of gender on the prevalence of diabetic retinopathy in people with DM [78].
While, in general, improvement in diabetic retinopathy status appears to be 
associated with improved glycaemic control and blood pressure, these factors can-
not be attributed to the greater chance of improvement observed in women com-
pared to men. Women in the UKPDS study were found to have a higher incidence 
of risk factors than the men in that study, including older age, more obesity, higher 
blood pressure, higher fasting plasma glucose levels, higher glycosylated haemo-
globin levels, higher plasma cholesterol levels, higher insulin levels and increased 
insulin resistance [77].
Study DR type Women (%) Men (%) P value Reference
CURES DR 15 21 <0.0001 Rema et al. 2005 [74]
GADPVD DR 22 24 <0.0001 Hammes et al. 2015 [75]
NHANES DR 26 32 <0.05 Zhang et al. 2010 [76]
V-DR 4 6 >0.05
UKPDS DR 35 39 None Kohner et al. 1998 [77]
V-DR 5 8 <0.001
CCSS DR 31 30 ns Liu et al. 2017 [78]
V-DR 14 14 ns
WESDR DR Hazard ratio men = 1.3 0.002 Klein et al. 2008 [79]
NHANES = The National Health and Nutrition Examination Survey, USA; UKPDS = The United Kingdom 
Prospective Diabetes Study; WESDR = Wisconsin Epidemiological Study of Diabetic Retinopathy, Wisconsin, 
USA; GADPVD = German/Austrian Diabetes-Patienten-Verlaufsdokumentation Database, Germany and Austria; 
CURES = Chennai Urban Rural Epidemiology Study, Chennai City, India; v-DR = vision-threatening DR. 
Statistically significant values bolded. ns = not significant; none = no statistical analysis performed.
Table 2. 
Prevalence of diabetic retinopathy in women and men with DM.
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It has been hypothesised alterations to sex hormone levels may be in part respon-
sible for the increased chance of retinopathy progression in males. Sex hormone-
binding globulin (SHBG) levels were found to be reduced in men who progressed to 
proliferative retinopathy as compared to those whose retinopathy did not progress over 
a 6 year period [80]. SHBG binds sex hormones, and lower levels allow for increased 
sex hormone activity, in men this would be associated with increased androgenicity.
2.3 Diabetic kidney disease
Diabetic kidney disease (DKD) is characterised by increased urinary albumin 
excretion in individuals living with DM who have not been diagnosed with any 
other renal disease [81]. It affects 20–40% of patients with T2DM and is the pri-
mary cause of kidney disease in patients who require renal replacement therapy 
[82]. Chronic Kidney Disease (CKD) in the absence of DM is more prevalent 
and more severe in men, but this gender disparity is not as striking in the case of 
DM-induced CKD (i.e. DKD) [83–85]. While some studies have found that men 
retain a significantly greater chance of developing DKD with DM [86, 87], others 
have found a similar prevalence of DKD women and men [88], see Table 3.
This increased relative risk in women mirrors the loss of protection from 
oestrogens seen in CVD rates in women with DM, and as per CVD, protection from 
CKD in women has also been recorded to be lost after menopause [90]. This, along 
with evidence from animal models supports a role for oestrogens and/or androgens 
in CKD progression that is blunted or lost in a DM setting [91, 92]. Mouse models 
of both menopause (ovariectomy) and DM demonstrate worsened nephropathy 
[93, 94]. The mechanism by which estradiol or other sex hormones may impact 
CKD risk is unknown but both direct action on the kidney (eg. podocyte viability) 
or indirect action (eg. due to increased blood pressure or via transforming growth 
factor-β (TGF-β)-induced collagen synthesis) have been posited [84, 95, 96].
2.4 Diabetic neuropathy
Diabetic neuropathy (DN) is one of the most frequently observed complications 
in diabetic populations, averaging at about 20% of people with T2DM globally – 
though much higher estimates are observed in older populations and in communi-
ties with suboptimal therapeutic adherence (eg. up to 66% in older women in rural 
South Carolina, USA) [97, 98]. DN is characterised by nerve damage resultant from 
hyperglycaemia, with a correlation between risk of development and the duration 
and severity of hyperglycaemia [99, 100]. Symptoms of diabetic neuropathy include 
pain, idiopathic sensations (paraesthesia), excessive sensitivity to stimulus, loss of 
Study Measure Women (%) Men (%) P value Reference
Saudi 
Arabia




18 35 0.02 Gall et al. 1997 [87]
NHANES Prevalence 39 40 None Wu et al. 2016 [88]
Korea Odds ratio (OR) OR for men = 1.31 0.0024 Yang et al. 2011 [89]
Statistically significant values bolded. None = no statistical analysis performed.
Table 3. 
Prevalence of diabetic kidney disease in women and men with DM.
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sensitivity, loss of coordination and altered sense of position [101]. These symptoms 
are associated with considerable morbidity, impacting quality of life [102]. The 
mechanism for nerve damage is through loss of protection and nutrient-provision 
from Schwann cells, leading eventually to axonal loss, most likely due to both high 
blood glucose levels and the absence of insulin, for which there are high affinity 
receptors throughout the nervous system [103, 104].
DN is the most significant contributor to diabetic foot syndrome (DFS) and 
results in a high risk of lower extremity amputation (LEA) among individuals 
living with DM [105]. DFS is characterised by the presence of foot ulcers and is 
causative of over 130,000 LEAs annually in the USA alone, this is approximately 
0.6% of people with DM in the USA [10, 106]. The percentage of people with DM 
who experience DFS and the percentage of those who go on to have an amputation 
vary between countries, with higher rates of amputation in Sub-Saharan Africa, the 
Caribbean and parts of Latin America [107, 108]. The USA also has a high rate when 
compared to other developed countries [109].
Generally, men have a younger onset of DN and more severe symptoms, includ-
ing higher rates of foot ulceration [100, 102, 110, 111]. Therefore, men are more 
likely to undergo a lower-extremity amputation (LEA) than women and at younger 
ages [102, 112–116], see Table 4. Globally, the number of people in 2016 who had 
amputations which were attributed to DM is 6.8 million people, with 4.1 million 
(60%) of those being men [107].
Although it has been hypothesised that lower rates of ulceration and/or LEA in 
women are due to indirect effects such as less physical work, superior preventative 
foot care and following care instructions [123–127], women and men have the same 
rate of ulceration when severity of DN is taken into account and equal rates of LEA 
within a population who have ulcers [111, 128]. Furthermore, though it has been 
reported that women heal ulcers more effectively than men [126], this study was in 
Prevalence of DN in diabetic populations by gender
Study location Women (%) Men (%) Significance Reference
Qatar 22 24 ns Ponirakis et al. 2020 [117]
India 8 10 P = 0.001 Sharath Kote et al. 2013 [118]
UK 19 23 P < 0.0001 Abbott et al. 2011 [97]
Bangladesh 19 21 None Mørkrid, Ali and Hussain 
2010 [119]
UK 29 29 None Young et al. 1993 [120]
Sri Lanka 26 20 p < 0.01 Katulanda et al. 2012 [121]






USA 28 55 p < 0.05 Correa-de-Araujo et al. 
2006 [122]
Sweden 192 197 None Johannesson et al. 2008 [113]
Spain 145 583 None Almaraz et al. 2012 [116]
USA 300 600 None Margolis et al. 2011 [112]
Statistically significant values bolded. ns = not significant; none = no statistical analysis performed.
Table 4. 
Prevalence of DN and incidence of LEA in women and men.
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the context of a therapeutic bioengineered human dermal substitute, while studies 
of ulcer healing generally demonstrate no effect of gender on ulcer healing [129].
Therefore, the physiological link between DN and gender remains unclear and 
interestingly height alone, with men being on average taller than women, may be 
the greatest predictor of the incidence of DN [130]. This may explain the regional 
variation in DN prevalence differences by gender, as average height also varies 
geographically. For example average adult male height in the USA (where men 
experience higher rates of DN) is 175 cm compared to men in Sri Lanka, (where 
lower rates of DN are recorded in men compared to women) and the average height 
of men is 166 cm. The absence of a direct effect of gender on DN is corroborated by 
studies in mice which demonstrate similar nerve tissue dysfunction in female and 
male mice [131].
DN can be classified as painful or insensate and interestingly, painful DN is 
more prevalent in women and does not correlate with height [97, 118, 130, 132, 133]. 
This specific form of DN has independent risk factors from overall DN and seri-
ously impacts on quality of life due to persistent sensation of pain in effected 
individuals [134, 135]. Why painful DN associates with the female gender is 
unknown but there is evidence of a genetic predisposition to the disorder based on 
high heritability [135]. This difference in painful DN between women and men may 
be attributable to the differences in pain processing, for which many hypotheses 
have been proposed to explain the differences present between genders, rather than 
differences related to DM or even DN specifically [136, 137].
2.5 Diabetic osteopathy
Bone health can be measured in a number of ways, including dual-energy x-ray 
absorptiometry (DXA) scan or measurement of bone turnover markers in the 
blood, however, the clinical importance of the disease lies in the elevated rate of 
fracture [138, 139]. In the non-diabetic population, the lifetime prevalence of hip 
fracture is significantly greater in women than in men [140]. This is driven by the 
higher rate of bone-turnover in postmenopausal women which results in decreased 
bone mineral density (BMD) culminating in osteoporosis [141–144]. As diagnosis 
and treatment for osteoporosis have increased, in conjunction with lower smok-
ing rates and higher average BMI, the rate of hip fracture is decreasing. However, 
with an ageing population the absolute number of hip fractures is predicted to 
increase [139, 140]. Compounding this challenge in managing orthopaedic health 
is the increased fracture risk in people living with T2DM [145–149]. Contrary to 
the osteoporotic context, this increase in fracture risk is despite generally increased 
BMD in the T2DM population [148, 150, 151].
T2DM is associated with a relative risk of hip fracture of 1.3 with greater 
 durations of T2DM increasing this risk [152, 153]. The presence of T2DM also 
increases the odds ratio of poor fracture healing, resulting in a malunion or non-
union [154]. Hospital stay length and mortality following orthopaedic procedures 
are also increased in people with T2DM [149, 155]. The increased risk of fracture is 
present in both women and men, with contradicting evidence regarding whether 
women or men are preferentially impacted in terms of fracture risk by T2DM, while 
worse outcomes post-operatively seem to be more prevalent in men [149, 152, 153, 
155, 156], see Table 5. Regardless, it is important that the increased risk of oste-
opathy in men with T2DM leads to appropriate intervention, where currently the 
emphasis of bone health is on women, in the T2DM context both women and men 
need to be considered.
Although DM-associated complications such as neuropathy and retinopathy 
increase the risk of falls which may result in fracture, the increased relative risk in 
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fracture remains when these variables are taken into account [159]. The reason for 
the increase in fracture risk in individuals with T2DM is not well characterised, but 
several hypotheses exist. DM induces systemic changes including inflammation and 
the generation of ROS which can negatively impact bone remodelling and changes 
in bone structure and mineral distribution [160–162], reviewed by [163]. People 
with T2DM have also been recorded as having lower density specifically of cortical 
bone and a more heterogeneous distribution of mineral, indicating compromising 
structural alterations that would yield impaired mechanical strength and increase 
the risk of fracture [160, 162]. Additionally, alterations to the mesenchymal stem 
cells (MSCs) responsible for maintaining bone homeostasis and for stimulating 
repair following an injury have also been reported [164–167]. Finally, pharmaceuti-
cal choice has also been reported to impact on the future risk of fracture in the 
DM population - thiazolidinediones have been associated with bone fragility while 
DPP4i and Metformin may reduce relative fracture risk [168–175].
In order to understand the gender aspect of the role of DM in bone health, 
recent publications investigated the aetiology of this increased fracture risk in men 
living with T2DM, identifying correlations with high levels of follicle-stimulating 
hormone and reduced estradiol with fracture risk [176]. There is also a discrepancy 
in the prescription of pharmaceuticals aimed at treating DM between women and 
men. For example, men are prescribed thiazolidinediones more often than women 
[177]. The disparity within the literature regarding the impact of gender in T2DM-
induced fracture risk indicates the complexity of the question, with confounding 
variables such as the impact of pharmaceuticals, age, BMI, duration of diabetes and 
the presence of other diabetes-associated comorbidities.
3. Conclusions
DM is a growing global pandemic. DM is associated with several severe complica-
tions which have a major impact on patient outcomes and quality of life, and which 
make up a considerable component of healthcare budgets worldwide. Diabetic 
complications include cardiovascular disease, retinopathy, nephropathy, neuropathy 
(including diabetic foot syndrome) and osteopathy. Gender has been proposed 
across numerous studies as an important variable in the risk of development of 
these complications. However, teasing apart the role of gender is complex. Both the 
physiological impact of sex and the psychosocial impact of gender on behaviour and 
treatment are confounded by numerous factors. These include direct and indirect 
biological traits that associate with each gender, from hormone levels (which are 
Study Measure Women Men Significance Reference
Korea HR 1.7 1.8 None Kim et al. 2017 [156]
USA HR 1.5 1.5 ns Melton et al. 2008 [143]
Scotland IRR 1- 1- ns Hothersall et al. 2014 [157]
Meta-Analysis RR 1.3 1.1 p < 0.001 Vilaca et al. 2020 [153]
RR 2.1 2.8 ns Janghorbani et al. 2007 [158]
RR 1.1 Baseline ns Fan et al.2016 [152]
Statistically significant values bolded.HR = hazard ratio; IRR = incidence risk ratio; RR = relative risk; ns = not 
significant; none = no statistical analysis performed.
Table 5. 
Summary of hip fracture risk in women and men living with T2DM.
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vastly different for women post-menopause) to average height, life span and access 
to appropriate treatment. Many of these biological traits, and also psychosocial and 
socioeconomic traits that impact risk vary widely geographically. Understanding 
the epidemiology and physiological mechanisms of DM-associated complications, 
including the role of gender, allows for the implementation of appropriate treatment 
and research programmes that ultimately reduce morbidity and mortality.
In the non-DM population, oestrogens such as estradiol are protective against 
some of these comorbidities but the protective effects are often diminished in a 
DM context. This pattern is evident in both CVD and CKD where women with DM 
undergo a much larger relative increase in risk compared to men. Numerous studies 
have also shown that women are less often prescribed ACE inhibitors and lipid low-
ering drugs, including statins [56–60]. This prescription bias compounds the higher 
rates of CVD and CKD in women with T2DM, leading to increased mortality rates, 
a major factor in the high T2DM-assocaited mortality in women [30]. Therefore, 
particular awareness needs to be paid to the gender discrepancy in patient care in 
the context of T2DM in order to address this inequality and improve outcomes for 
women living with T2DM.
The onset of diabetic retinopathy is also linked to sex hormones - with levels 
of androgens correlating to likelihood of diagnosis. There is therefore increased 
incidence of diabetic retinopathy in men compared to women. Contrasting to 
this, neuropathy incidence, though higher in men, does not correlate directly with 
gender but instead with height which is a predictor of neuropathy development in 
both diabetic and non-diabetic populations [111, 118]. Therefore the higher rates 
in men in many regions are likely due to the greater average height of men with the 
causality possibly being longer nerve fibres which are more susceptible to injury 
and take longer to heal [111, 118].
Diabetic osteopathy is one of the less-reported complications of DM. People liv-
ing with T2DM experience higher fracture rates both due to increased rates of fall-
ing and due to poorer bone health, which is present despite increased BMD [159]. In 
terms of the role of gender in diabetic osteopathy, the disorder follows an opposite 
pattern to that seen in CVD and DKD. Poor bone health experienced primarily by 
women in the non-DM population as they age is largely absent in men, but in the 
context of DM there is an increased relative risk for men to experience, for example, 
hip fracture [149, 156]. Fractures such as these are associated with high morbidity, 
especially functional limitations that results in loss of independence – physically 
and economically [178].
Interestingly, the overall mortality rates and cost of treatment associated with 
DM are higher in women than in men despite the general preponderance of comor-
bidity in men. A number of factors may explain this discrepancy. Firstly, women 
with DM are older, and epidemiologically there is increased cost of treatment and 
higher mortality with age. Secondly, regions with high DM-associated mortality 
(low- and middle-income countries) also report higher rates of DM in women [1]. 
Finally, men are reported to develop DM with a reduced risk-factor burden (eg. 
lower BMI). Though this indicates a greater risk of DM development for men, it 
also signifies that women, once they do develop DM, are diagnosed with such along 
with a greater set of risk factors for DM complications. These risk factors include 
inadequate blood glucose control, high blood pressure, high BMI and reportedly 
less frequent exercise [179]. Though not all women will experience pregnancy, for 
those that do, their glycaemic control during this time is a strong predictor of future 
development of T2DM [180]. Targeting those women who experience gestational 
diabetes for education or treatment options for T2DM would be an effective way of 
reducing diabetic burden in women and therefore reducing associated morbidity 
and mortality of T2DM globally [181, 182].
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With such a large proportion of society effected by DM and the fact that the 
major risk factors for T2DM comprise a generally unhealthy lifestyle, the lines 
between complications of the disease itself and disorders that are simply comor-
bid, but potentially highly important and relevant to the DM population, become 
blurred. For example, T2DM is a risk factor for vascular dementia, more so in 
women compared to men [183]. Women with T2DM also have increased depres-
sive symptoms compared to men with T2DM and these symptoms correlate with 
worsening T2DM biological profiles [179]. Studying the role of gender in this 
wider range of comorbidities will be important for a greater understanding of the 
interplay between common modifiable risk factors and those non-communicable 
diseases that are increasing in prevalence worldwide. This will ultimately benefit 
the future wellbeing of those that live with DM.
Gender also plays a role in response to and adherence to medication. While it 
has been demonstrated that there is no overall difference in medication adherence 
between women and men, Walker et al. demonstrated a significantly reduced 
adherence to Metformin in women and this was specifically related to women 
reporting worse adverse effects from the drug [179, 184]. Although advancements 
in therapies for DM include expensive pharmaceutical agents which are likely to 
increase the cost of treatment of DM per patient, significant reduction to overall 
spend may be achieved through effective reduction of complications [185]. Fewer 
complications and reduced severity of complications are not only beneficial for the 
overall costs of DM but also due to the obvious significant reduction in morbidity 
and mortality that would be associated. It is important that current and future 
medications are assessed for differential effects between women and men. A more 
recently explored treatment option, which has potential to rescue many of the 
disorders associated with T2DM is cell therapy. For many DM comorbidities, MSCs, 
for example, have been proposed as having a mechanistic role in both pathology 
and/or recovery [165, 186, 187]. There are fewer MSCs in the bone marrow of people 
with T2DM and considering the role of MSCs in repair and in reduction of inflam-
mation, they are well poised as an effective treatment option [165]. Furthermore, 
there does not appear to be an impact of gender on the functioning of MSCs in 
tissue repair indicating they could benefit both women and men with T2DM comor-
bidity [165].
In conclusion, there are important implications of gender in terms of the risk 
of DM itself and subsequently the disorders caused by and associated with it. 
These differences need to be taken into account in research into T2DM and its 
complications as well as in the treatment of those individuals diagnosed with 
the disease. The observed interplay between T2DM and gender warrants further 
epidemiological and molecular analyses in order to achieve a more complete 
understanding of the role of gender in the onset and prognosis of diabetic com-
plications. This review also demonstrates that in terms of biomedical research it 
is of crucial importance for studies to include both genders in their research, and 
for gender to be recorded as a variable. This supports recommendations made by 
the SAGER (Sex and Gender Equity in Research) guidelines [188]. It will also be 
important to further study the mechanism by which gender exerts the described 
effects, which will be different for different comorbidities of DM, and will likely 
vary by region.
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